BioMedNewsBreaks Archive - Page 118 of 233

FridayDec 16, 2022 2:59 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Adds Renowned Cardiologist to Help Define Best Paths to Advance Products

HeartBeam (NASDAQ: BEAT), a cardiac technology company, recently named a world-renowned interventional cardiologist with an impressive breadth of experience as its chief medical officer. “Stanford cardiologist Peter J. Fitzgerald, MD, PhD, will help HeartBeam continue to develop the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere… Dr. Fitzgerald joins HeartBeam after gaining invaluable experience in the clinical, research and industry sectors. An accomplished inventor, entrepreneur and investment-fund founder, Dr. Fitzgerald is serving as director of the Center for Cardiovascular Technology and director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School,” a recent article…

FridayDec 16, 2022 12:12 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Pricing on Public Offering, Expects to Raise $8M

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the pricing of its underwritten public offering. According to the announcement, the company anticipates gross proceeds from the offering, which consists of 1,600,000 units and prefunded units, to reach an estimated $8 million. The company specified that each unit consists of one American Depositary Share (“ADS”) and two warrants; one warrant will expire three years from the date of issuance with the second warrant set to expire one year from the date of issuance.…

FridayDec 16, 2022 10:22 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Shares Annual General Meeting Results

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, is reporting on the results of its 2022 annual meeting. The meeting of shareholders was held Dec. 15, 2022. During the meeting, shareholders considered and voted on all matters outlined in InMed’s notice of meeting and management information circular. Specifically, the election of directors was held, and shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders. Those directors included Eric Adams, Andrew Hull, Janet Grove, Bryan Baldasare, and Nicole Lemerond. To view…

WednesdayDec 14, 2022 3:55 pm

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Approval to Dual List, to Commence Trading on Upstream

Nutriband (NASDAQ: NTRB, NTRBW) has announced its approval to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex and MERJ Exchange Limited. The company’s trading is expected to commence on Upstream under ticker symbol NTRB at 10:00am ET on Jan. 5, 2023. “Building shareholder value and increasing our liquidity is always a high priority for us,” said Gareth Sheridan, CEO of Nutriband. “We believe a dual listing on Upstream will act as an excellent vehicle to reach an untapped international market of potential new shareholders. As we continue to develop…

WednesdayDec 14, 2022 2:14 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Berubicin Program Forward

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments, recently announced that the first patient in Europe had been enrolled and dosed in France in the company’s ongoing global trial to evaluate Berubicin for the treatment of recurrent glioblastoma multiforme (“GMB”), an aggressive and incurable form of brain cancer. “Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier (based upon pre-clinical and limited clinical data) and is currently being evaluated in the potentially pivotal study evaluating efficacy and safety for GBM treatment. This study is an adaptive,…

TuesdayDec 13, 2022 3:47 pm

BioMedNewsBreaks – IBN, BioMedWire to Deliver Increased Visibility, Reach for DGE’s 2023 Events

IBN (“InvestorBrandNetwork”), a multifaceted communications organization engaged in connecting companies to the investment community through 50+ brands, has announced that it will collaborate with Dynamic Global Events (“DGE”) as an official media partner for upcoming events in 2023. In addition, BioMedWire (“BMW”), a specialized communications platform for the life sciences sector and one of IBN’s 50+ brands, will serve as an official media partner for DGE’s events throughout the coming year. A world leader in life sciences-related conference production, DGE has developed a portfolio of high-quality B2B events that facilitate partnership-building, education and networking throughout the pharmaceutical, health care and…

TuesdayDec 13, 2022 3:41 pm

BioMedNewsBreaks – Keros Therapeutics Inc. (NASDAQ: KROS) Presents Clinical and Preclinical Data from Its Lead Hematological Programs at 64th ASH Event

Keros (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders, announced that it presented clinical and preclinical data at the 64th American Society of Hematology (“ASH”) Annual Meeting and Exposition. The event was held in person and virtually from Dec. 10 -13, 2022. “We are pleased to present clinical and preclinical data from our lead hematological programs at ASH this year. In our ongoing phase 2 clinical trial in MDS, we observed a sustained response with longer-term treatment with KER-050 across all transfusion burdens.…

TuesdayDec 13, 2022 2:53 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in ‘Stock2Me’ Podcast

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in the latest episode of the Stock2Me Podcast, an IBN solution to provide specialized content distribution via widespread syndication channels. BiondVax’s CEO Amir Reichman joined the latest episode to introduce the company and discuss its recent development efforts focused on innovative nanosized antibody (“NanoAb”) therapies addressing diseases underserved by current treatments and with large and growing markets. “[While attempting to develop the universal influenza vaccine], BiondVax built a state-of-the-art facility in Jerusalem. It’s a…

TuesdayDec 13, 2022 10:26 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Interim Chief Financial Officer, Changes Auditor

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announced that Jonathan Tegge, a member of Brio Financial Group, will shoulder the role of interim CFO effective Dec. 12, 2022. The announcement accompanied the news that InMed has signed a service contract with Brio Financial Group to provide senior financial leadership and bookkeeping services. A financial and management consulting group based in New Jersey, Brio outsources financial management and financial reporting support to small- and middle-market entities. Currently, the Brio team provides consulting services to some 50 private and publicly traded…

MondayDec 12, 2022 12:33 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Regains Compliance with Nasdaq Listing Rules

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the receipt of formal notifications from the Nasdaq Stock Market that the company has regained Nasdaq compliance regarding minimum stockholders’ equity and minimum bid price. The company previously reported receipt of the respective non-compliance notifications on Sept. 30 and Nov. 2, 2022. According to the update, Nasdaq indicated that it has determined, based on BiondVax’s Form 6-K dated Nov. 30, 2022, reporting third-quarter financial results, that the company once again complies with Listing Rule…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Adds Renowned Cardiologist to Help Define Best Paths to Advance Products

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Pricing on Public Offering, Expects to Raise $8M

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Shares Annual General Meeting Results

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Approval to Dual List, to Commence Trading on Upstream

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Berubicin Program Forward

BioMedNewsBreaks – IBN, BioMedWire to Deliver Increased Visibility, Reach for DGE’s 2023 Events

BioMedNewsBreaks – Keros Therapeutics Inc. (NASDAQ: KROS) Presents Clinical and Preclinical Data from Its Lead Hematological Programs at 64th ASH Event

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in ‘Stock2Me’ Podcast

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Interim Chief Financial Officer, Changes Auditor

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Regains Compliance with Nasdaq Listing Rules

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search